Cinda Biotech and Baoyuan Pharmaceutical announce the interim data of the phase II trial of Taletrectinib in ROS1-positive non-small cell lung cancer at the CSCO annual meeting in 2021

San Francisco, USA and Suzhou, China September 27, 2021/PRNewswire/ - Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801) ("Cinda Bio"), a company dedicated to R&D, production and sales Biopharmaceutical companies specializing in innovative drugs for the treatment of tumors, metabolic diseases, autoimmunity and other major diseases, and Baoyuan Biomedical Technology (Hangzhou) Co.

The title of the conference theme report is "Taletrectinib (AB-106): A new generation of potent ROS1/NTRK inhibitors for the treatment of ROS1-positive non-small cell lung cancer Phase II study (TRUST study) preliminary study results"

As of June 16, 2021, a total of 21 patients who have not been treated with crizotinib and 16 patients who have received crizotinib have been confirmed to be ROS1 positive.

Among 21 patients who did not receive crizotinib treatment, the confirmed objective response rate (ORR) was 90.

Professor Zhou Caicun, Director of the Department of Oncology of Shanghai Pulmonary Hospital, said: “We are pleased to see that the interim data of Phase II initially shows that Taletrectinib is safe and tolerable, and it is very promising to become a new therapy for ROS1-fusion-positive lung cancer.

Dr.

Dr.

About Taletrectinib

Taletrectinib is a new generation of tyrosine kinase inhibitor (TKI) under development.

About Cinda Bio

"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio

Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi of South Korea.

statement:

1.

2.

3.

About Baoyuan Pharmaceutical

Baoyuan Biomedical Technology (Hangzhou) Co.

Cinda Biosciences forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made
.
These statements are not guarantees for future development and will be affected by risks, uncertainties and other factors.
Some of them are beyond the control of the company and are difficult to predict
.
Therefore, due to future changes and developments in our business, competitive environment, political, economic, legal and social conditions, actual results may differ significantly from the information contained in the forward-looking statements
.

Baoyuan Pharmaceutical's forward-looking statements

Statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995
.
These statements are subject to known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, activity levels, performance or achievements to be materially different from those anticipated in these statements
.
In some cases, you can pass information such as "may", "will", "should", "expect", "plan", "forecast", "believe", "estimate", "forecast", "potential", Terms such as "intend" or "continue", or other negatives similar to these terms, are used to identify forward-looking statements
.
The forward-looking statements contained in this article include, but are not limited to, (1) statements about the expected clinical trial time of our candidate products and our R&D plan; (2) the time when the clinical data of our candidate products are obtained; (3) our comments on the candidate products (4) The size of the patient population targeted by our candidate products and the market adoption rate of our candidate products by doctors and patients; and (5) The time or period of application and approval to regulatory agencies Possibility
.
Unless required by law, even if new information is updated in the future, we are not obliged to publicly update these forward-looking statements, or to update the reasons why actual results may differ materially from those anticipated in the forward-looking statements
.
This article will discuss candidate products that are undergoing clinical studies, which have not yet been approved for marketing by the US Food and Drug Administration or regulatory agencies in other countries
.
No statement is made about the safety or effectiveness of the candidate products under study
.

Source: Cinda Bio